

**Peer Review File**

**Article information: <https://dx.doi.org/10.21037/cco-23-40>**

**Reviewer A**

This is a nicely written Editorial highlighting several aspects in the current controversy around the main publication.

**Reviewer B**

A nicely written commentary on the recently published JAMA Oncology piece on the CHALLENGE trial. Thoughtful examination of the paper while putting into context the current clinical practice landscape for patients with NSCLC. Sound recommendations provided overall. This is a fine editorial on the JAMA Onc piece. Really nothing to add, should be fine to accept and publish.